p16 Mutation Spectrum in the Premalignant Condition Barrett's Esophagus

Thomas G. Paulson, Patricia C. Galipeau, Lianjun Xu et al. · 2008

Read p16 Mutation Spectrum in the Premalignant Condition Barrett's Esophagus by Thomas G. Paulson, Patricia C. Galipeau, Lianjun Xu et al. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0003809.txt.

Introduction

Thomas G. Paulson, Patricia C. Galipeau, Lianjun Xu, and colleagues published this cancer study in PLOS ONE in 2008. The tumor suppressor gene p16 is altered in many human cancers. Barrett's esophagus is a premalignant change in the food pipe, often from chronic reflux. How often p16 mutates there was much less known.

The team charted the spectrum of p16 mutations in Barrett's tissue. They set those point changes beside other p16 damage known from cancers. The pattern helps mark the genetic road from a reflux-damaged esophagus toward cancer, and where checks might catch it early.

Catalog record

CREATORThomas G. Paulson, Patricia C. Galipeau, Lianjun Xu et al.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE31 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0003809

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

p16 Mutation Spectrum in the Premalignant Condition Barrett's Esophagus Authors: Thomas G. Paulson, Patricia C. Galipeau, Lianjun Xu, Heather D. Kissel, Xiaohong Li, Patricia L. Blount, Carissa A. Sanchez, Robert D. Odze, Brian J. Reid Published: 2008, PLOS ONE DOI: 10.1371/journal.pone.0003809 ABSTRACT Mutation, promoter hypermethylation and loss of heterozygosity involving the tumor suppressor gene p16 (CDKN2a/INK4a) have been detected in a wide variety of human cancers, but much less is known concerning the frequency and spectrum of p16 mutations in premalignant conditions. We have determined the p16 mutation spectrum for a cohort of 304 patients with Barrett's esophagus, a premalignant condition that predisposes to the development of esophageal adenocarcinoma. Forty seven mutations were detected by sequencing of p16 exon 2 in 44 BE patients (14.5%) with a mutation spectrum consistent with that caused by oxidative damage and chronic inflammation. The percentage of patients with p16 mutations increased with increasing histologic grade. In addition, samples from 3 out of 19 patients (15.8%) who underwent esophagectomy were found to have mutations. The results of this study suggest the environment of the esophagus in BE patients can both generate and select for clones with p16 mutations. INTRODUCTION p16 (CDKN2a/INK4a) (OMIM #600160) is a cyclin dependent kinase inhibitor that regulates cell cycle progression through the G1/S restriction point by binding to cyclin dependent kinases 4 and 6, preventing phosphorylation of the retinoblastoma protein [1] , [2] . Germline mutations in p16 have been associated with familial melanoma syndromes [3] , and somatic alterations in p16 have been detected in a wide variety of cancers [4] , [5] . These alterations occur by multiple mechanisms, including mutation, loss of heterozygosity (LOH) and promoter hypermethylation. Given its role in modulating cell proliferation, it is not surprising that p16 alterations are one of the most common genetic/epigenetic alterations in cancer. Barrett's esophagus (BE) is a premalignant condition in which the squamous epithelium that normally lines the esophagus is replaced with specialized intestinal epithelium as a result of chronic gastroesophageal reflux [6] . Patients with BE have a 30–40 fold increased risk of developing esophageal adenocarcinoma (EA), a cancer that has increased in incidence more than 600% over the past three decades (1972–2002) [7] – [9] . EA and esophageal squamous cell carcinoma (SCC) are the two major types of cancer that develop in the esophagus. In contrast to EA, SCC rates have declined in the US over the same time period [9] . Both types of esophageal cancer are thought to be promoted by environmental exposures (smoking and alcohol use for SCC, chronic gastroesophageal reflux for EA), but the molecular pathways involved with neoplastic progression in these two cancers are thought to be different [10] . A number of studies have examined the involvement of p16 mutations in esophageal cancer [4] , [11] – [15] , the majority of which have focused primarily upon SCC. Less is know concerning the frequency and spectrum of p16 mutations in EA, and very little about p16 mutations in BE. Here, we report p16 mutation detection and characterization in a prospective cohort study of 304 patients with BE and from 19 patients for which esophagectomy samples were available. We find p16 mutations can occur very early during neoplastic progression in BE, and the spectrum of mutation is consistent with that of oxidative damage that can be generated as a result of chronic reflux. MATERIALS AND METHODS Patients were enrolled in The Seattle Barrett's Esophagus Research Program, a dynamic cohort study that began in 1983. All participants in this study were recruited from this continuing program of cancer surveillance in which participants undergo periodic endoscopy with multiple biopsies following a standard protocol [16] . The study was approved by the Human Subjects Division of the University of Washington in 1983 and renewed annually thereafter with reciprocity from the Fred Hutchinson Cancer Research Center from 1993 to 2001. Since 2001, the study has been approved annually by the IRB of the FHCRC with reciprocity from the Human Subjects Division of the University of Washington. Flow-sorted samples from multiple biopsies of Barrett's epithelium were evaluated from 304 patients who at baseline endoscopy had BE without cancer. Of the 304 patients, 235 were male (77%) and 69 were female (23%). The mean age of the patients was 62.7 years (range 30.5 to 87.3) ( Table 1 ). This study was conducted at a specialty research and referral center, and thus our cohort is considered a high-risk patient population. Biopsies were acquired at 2-cm intervals throughout the Barrett's segment using endoscopic mapping protocols described previously [16] – [19] . Normal gastric tissue served as a constitutive control for each patient. Patients were counseled regarding the risks and benefits of endoscopic surveillance and informed of potential alternative therapies, including surgery and endoscopic ablation, for high-grade dysplasia. Written informed consent for research use of biopsies and esophagectomy specimens was obtained from all patients in this study. Samples from 27 patients who had undergone esophagectomy were also examined for p16 mutation. Eight of these patients also had samples from a baseline endoscopy and were removed from analysis of frequency of mutation to prevent duplication of data. TABLE: Cohort characteristics. Patients with endoscopic samples Male 235 Female 69 Average age 63 (range 30 to 87) Average # biopsies per patient 4.4 Diagnosis Mutation frequency High-grade dysplasia 12/61 (19.7%) Low-grade/Indefinite 27/153 (17.6%) Metaplasia 5/90 (5.5%) All 44/304 (14.5%) Patients with esophagectomy samples Male 18 Female 1 Average age 67 (range 43 to 93) Average # biopsies per patient 5.4 Diagnosis Mutation frequency EA 1/13 (6.25%) High-grade dysplasia 1/3 (33.3%) Low-grade/Indefinite 1/1 (100.0%) Metaplasia 0/0 (NA) Unknown 0/2 (0.0%) All 3/19 (15.8%) HISTOLOGY Endoscopic biopsies were processed and interpreted for grade of dysplasia. Mutation at p16 was assessed in biopsies taken at levels adjacent to those used for histology and patients were classified according to the maximum histologic grade of dysplasia in any biopsy, as described previously [16] , [17] , [19] . Of the 304 patients, 90 were negative for dysplasia, 95 were indefinite for dysplasia, 58 had low-grade dysplasia range (LGD), and 61 had high-grade dysplasia (HGD) ( Table 1 ). The maximum histologic grade of the samples from the esophagectomies ranged from unknown (n = 2) to low-grade/indefinite for dysplasia (1), high-grade dysplasia (8), up through EA (16). Histologic or p16 mutation data from previous endoscopies from many of these patients were not available; because of this, data from the esophagectomy specimens was analyzed separately from that obtained from endoscopic biopsies. FLOW CYTOMETRIC SORTING AND DNA EXTRACTION Barrett's epithelial cell populations were purified from endoscopic biopsies and esophagectomy samples by means of Ki67/DNA content flow sorting of diploid G1, 4N, and aneuploid cell populations on a Coulter Elite ESP cell sorter, as described previously [20] – [22] . This process enriches for epithelial cell (BE) populations and removes underlying genotypically normal stromal cells, allowing less ambiguous detection and characterization of mutations. DNA SEQUENCING Evaluation of mutations in exon 2 of the p16 gene was performed on an aliquot of genomic DNA that had undergone whole genome amplification (PEP) [23] as previously described [24] . We sequenced exon 2 of p16 since the vast majority of p16 mutations reported in

Read the complete text